Montalto, Giuseppe

Targeting GSK3 and Associated Signaling Pathways Involved in Cancer

Duda, P., Akula, S. M., Abrams, S. L., Steelman, L. S., Martelli, A. M., Cocco, L., Ratti, S., Candido, S., Libra, M., Montalto, G., et al. (2020) · Cells

Wnt/β-catenin signaling in development and cancerPI3K/AKT/mTOR signaling in cancer

Cited by 284

GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms

Rizzo, M., Nikolic, D., Patti, A. M., Mannina, C., Montalto, G., McAdams, B. S., Rizvi, A. A., & Cosentino, F. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 152

Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study

Rizzo, M., Rizvi, A. A., Patti, A. M., Nikolic, D., Giglio, R. V., Castellino, G., Li Volti, G., Caprio, M., Montalto, G., Provenzano, V., et al. (2016) · Cardiovascular Diabetology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 135

The role of fibrate treatment in dyslipidemia: an overview

Katsiki, N., Nikolic, D., Montalto, G., Banach, M., Mikhailidis, D. P., & Rizzo, M. (2013) · Current Pharmaceutical Design

Lipoproteins and Cardiovascular HealthPeroxisome Proliferator-Activated Receptors

Cited by 131

Liraglutide Reduces Oxidative Stress and Restores Heme Oxygenase-1 and Ghrelin Levels in Patients with Type 2 Diabetes: A Prospective Pilot Study

Rizzo, M., Abate, N., Chandalia, M., Rizvi, A. A., Giglio, R. V., Nikolic, D., Marino Gammazza, A., Barbagallo, I., Isenovic, E. R., Banach, M., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Treatment and ManagementHeme Oxygenase-1 and Carbon Monoxide

Cited by 113

Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect

Nikolic, D., Giglio, R. V., Rizvi, A. A., Patti, A. M., Montalto, G., Maranta, F., Cianflone, D., Stoian, A. P., & Rizzo, M. (2021) · Diabetes Therapy

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 81

Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality

Barylski, M., Toth, P. P., Nikolic, D., Banach, M., Rizzo, M., & Montalto, G. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 67

Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals

Abrams, S. L., Lertpiriyapong, K., Yang, L. V., Martelli, A. M., Cocco, L., Ratti, S., Falasca, M., Murata, R. M., Rosalen, P. L., Lombardi, P., et al. (2018) · Advances in Biological Regulation

Pancreatic and Hepatic Oncology ResearchCancer-related Molecular Pathways

Cited by 36